Lexaria Bioscience (LEXX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Lexaria Bioscience has launched a 12-week Phase 1b study to assess if its DehydraTECH technology can enhance the safety and effectiveness of GLP-1 drugs, potentially reducing side effects and improving efficacy. This study, involving various capsules and tablets, aims to provide significant insights into diabetes control and weight loss management. Conducted across seven sites in Australia, the study’s findings may align with FDA standards.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
